[go: up one dir, main page]

AR056575A1 - Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo - Google Patents

Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo

Info

Publication number
AR056575A1
AR056575A1 ARP060104441A ARP060104441A AR056575A1 AR 056575 A1 AR056575 A1 AR 056575A1 AR P060104441 A ARP060104441 A AR P060104441A AR P060104441 A ARP060104441 A AR P060104441A AR 056575 A1 AR056575 A1 AR 056575A1
Authority
AR
Argentina
Prior art keywords
prolinamide
fluorophenyl
alpha
phenyl
prepare
Prior art date
Application number
ARP060104441A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR056575A1 publication Critical patent/AR056575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuesto de alfa-aminocarboxiamida que es 5-(4-{[(2-fluorofenil)metil]oxi}fenil)prolinamida de formula (1) o su sal farmacéuticamente aceptable solvato o profármaco, como ser el hidrocloruro. Dicho compuesto en forma cristalina. Composicion farmacéutica que lo comprende y su uso para la fabricacion de un medicamento para tratar o prevenir una enfermedad o trastorno mediados por la modulacion de los canales de sodio con apertura por voltaje (ôvoltaje-gatedö), dependientes del uso, como ser depresion o trastorno del estado emocional, trastorno bipolar o relacionado con sustancias. Proceso para preparar dicho compuesto.
ARP060104441A 2005-10-10 2006-10-09 Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo AR056575A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
AR056575A1 true AR056575A1 (es) 2007-10-10

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104441A AR056575A1 (es) 2005-10-10 2006-10-09 Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo

Country Status (20)

Country Link
US (2) US7655693B2 (es)
EP (1) EP1934177B8 (es)
JP (1) JP5139305B2 (es)
KR (1) KR101282464B1 (es)
AR (1) AR056575A1 (es)
AT (1) ATE556049T1 (es)
AU (1) AU2006301470B2 (es)
BR (1) BRPI0616944B8 (es)
CA (1) CA2625642C (es)
CR (1) CR9898A (es)
EA (1) EA015736B1 (es)
ES (1) ES2387405T3 (es)
IL (1) IL192627A0 (es)
MA (1) MA29817B1 (es)
NO (1) NO20082145L (es)
NZ (1) NZ567051A (es)
PE (1) PE20070592A1 (es)
PL (1) PL1934177T3 (es)
TW (1) TW200730494A (es)
WO (1) WO2007042239A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
JP2013501026A (ja) * 2009-08-05 2013-01-10 クオンベルゲンセ プハルマセウトイカルス リミテッド てんかん及び関連疾患の治療のための共治療法
PT2477964E (pt) 2009-09-14 2015-06-04 Convergence Pharmaceuticals Processo para a preparação de derivados de alfa-carboxamida
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
WO2015130905A1 (en) 2014-02-27 2015-09-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
BR112019008913A2 (pt) * 2016-11-02 2019-08-06 Biogen Ma Inc novo regime de dosagem
CA3062884A1 (en) * 2017-05-19 2018-11-22 Biogen Ma Inc. Novel crystalline forms
CA3076823A1 (en) * 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2019075073A2 (en) 2017-10-10 2019-04-18 Biogen Inc. PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES
MX2020010929A (es) * 2018-04-16 2020-11-06 Biogen Ma Inc Metodos para tratar el dolor neuropatico.
EA202192764A1 (ru) * 2019-04-10 2022-03-10 Байоджен Инк. Способы получения производных альфа-карбоксамид пирролидина
MX2021012420A (es) * 2019-04-10 2022-02-10 Biogen Ma Inc Proceso para preparar derivados de pirrolidina alfa-carboxamida.
US20230105795A1 (en) 2020-01-30 2023-04-06 Mohammad JAVED Combination drug therapies for cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
AU782353B2 (en) 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PA8583001A1 (es) 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
EP1615895A4 (en) 2003-04-03 2007-11-07 Merck & Co Inc SUBSTITUTED BIARYL PYRAZOLES AS SODIUM CHANNEL BLOCKERS
US20070060584A1 (en) 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
JP2008540438A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリジン
EP1877385A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
JO2722B1 (en) * 2005-09-09 2013-09-15 سميث كلاين بيتشام كوربوريشن New vehicles
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
IL192627A0 (en) 2011-08-01
EP1934177A1 (en) 2008-06-25
CR9898A (es) 2008-07-29
ATE556049T1 (de) 2012-05-15
TW200730494A (en) 2007-08-16
EA200801054A1 (ru) 2008-08-29
EA015736B1 (ru) 2011-10-31
AU2006301470B2 (en) 2012-06-14
US20100105754A1 (en) 2010-04-29
ES2387405T3 (es) 2012-09-21
KR20080059296A (ko) 2008-06-26
US7655693B2 (en) 2010-02-02
JP5139305B2 (ja) 2013-02-06
EP1934177B8 (en) 2012-09-05
US8153681B2 (en) 2012-04-10
BRPI0616944A2 (pt) 2011-07-05
WO2007042239A1 (en) 2007-04-19
BRPI0616944B8 (pt) 2021-05-25
EP1934177B1 (en) 2012-05-02
NZ567051A (en) 2011-03-31
NO20082145L (no) 2008-05-07
BRPI0616944B1 (pt) 2020-04-14
JP2009511519A (ja) 2009-03-19
US20080280969A1 (en) 2008-11-13
PE20070592A1 (es) 2007-06-23
MA29817B1 (fr) 2008-09-01
CA2625642A1 (en) 2007-04-19
PL1934177T3 (pl) 2013-03-29
KR101282464B1 (ko) 2013-07-04
CA2625642C (en) 2013-12-24
AU2006301470A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
AR056575A1 (es) Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
UY28489A1 (es) Glucopiranosiloxi-pirazoles, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR11470A (es) Compuestos organicos
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
AR077638A1 (es) Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
AR057869A1 (es) Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
BR112012020557A8 (pt) formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
AR055009A1 (es) Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento
AR106180A2 (es) COMPUESTO DE a-AMINOCARBOXIAMIDA QUE ES 5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)PROLINAMIDA

Legal Events

Date Code Title Description
FC Refusal